Business
Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD
TOKYO & WALTHAM, Mass., December 25, 2025--Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled "Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD" has been published in the peer-reviewed journal Human Gene Therapy.
About this update from Modalis Therapeutics Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":312,"url":"https://media.zenfs.com/en/business-wire.com/3fb74ed90edbb1198be642adaa4d6840"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1nlBhdDZ4yISR_asF1gnVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYyNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3fb74ed90edbb1198be642adaa4d6840","width":480,"height":312}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"CRISPR-GNDM® platform achieves potent and specific activation of LAMA1 with therapeutic benefit in preclinical models","length":117,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Favorable safety and pharmacodynamics demonstrated in non-human primates","length":72,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":189,"olType":false},{"type":"text","content":"TOKYO & WALTHAM, Mass., December 25, 2025--(BUSINESS WIRE)--Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled "Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD" has been published in the peer-reviewed journal Human Gene Therapy.","length":332,"tagName":"p"},{"type":"text","content":"The publication highlights compelling preclinical evidence that Modalis’ proprietary CRISPR-GNDM® epigenome editing technology can safely and robustly activate the LAMA1 gene as a novel therapeutic strategy for LAMA2-related congenital muscular dystrophy (LAMA2-CMD), a severe pediatric neuromuscular disorder with no approved treatments.","length":338,"tagName":"p"},{"type":"text","content":"Key findings include:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Robust, muscle-specific activation of LAMA1 following a single administration of muscle-tropic AAV vectors encoding the GNDM activator","length":134,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Marked improvement in survival and muscle function in DyW mouse models, including dose-dependent increases in grip strength and normalization of muscle histology","length":161,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Favorable safety and pharmacodynamic profiles in non-human primates (NHPs), with stron...